Adult phenotype of KCNQ2 encephalopathy

J Med Genet. 2022 Jun;59(6):528-535. doi: 10.1136/jmedgenet-2020-107449. Epub 2021 Apr 2.

Abstract

Background: Pathogenic KCNQ2 variants are a frequent cause of developmental and epileptic encephalopathy.

Methods: We recruited 13 adults (between 18 years and 45 years of age) with KCNQ2 encephalopathy and reviewed their clinical, EEG, neuroimaging and treatment history.

Results: While most patients had daily seizures at seizure onset, seizure frequency declined or remitted during childhood and adulthood. The most common seizure type was tonic seizures (early) infancy, and tonic-clonic and focal impaired awareness seizures later in life. Ten individuals (77%) were seizure-free at last follow-up. In 38% of the individuals, earlier periods of seizure freedom lasting a minimum of 2 years followed by seizure recurrence had occurred. Of the 10 seizure-free patients, 4 were receiving a single antiseizure medication (ASM, carbamazepine, lamotrigine or levetiracetam), and 2 had stopped taking ASM. Intellectual disability (ID) ranged from mild to profound, with the majority (54%) of individuals in the severe category. At last contact, six individuals (46%) remained unable to walk independently, six (46%) had limb spasticity and four (31%) tetraparesis/tetraplegia. Six (46%) remained non-verbal, 10 (77%) had autistic features/autism, 4 (31%) exhibited aggressive behaviour and 4 (31%) destructive behaviour with self-injury. Four patients had visual problems, thought to be related to prematurity in one. Sleep problems were seen in six (46%) individuals.

Conclusion: Seizure frequency declines over the years and most patients are seizure-free in adulthood. Longer seizure-free periods followed by seizure recurrence are common during childhood and adolescence. Most adult patients have severe ID. Motor, language and behavioural problems are an issue of continuous concern.

Keywords: and neonatal diseases and abnormalities; congenital; epilepsy; genetics; hereditary; medical; phenotype; prognosis.

MeSH terms

  • Adult
  • Anticonvulsants / therapeutic use
  • Brain Diseases* / drug therapy
  • Brain Diseases* / genetics
  • Electroencephalography
  • Epilepsies, Partial*
  • Humans
  • Intellectual Disability* / genetics
  • KCNQ2 Potassium Channel / genetics
  • Phenotype
  • Seizures / drug therapy
  • Seizures / genetics

Substances

  • Anticonvulsants
  • KCNQ2 Potassium Channel
  • KCNQ2 protein, human